Showing 1071-1080 of 6808 results for "".
Identifying SCC Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/identifying-scc-risk/20144/Sherrif Ibrahim, MD discusses the challenges of managing squamous cell carcinoma (SCC). Great steps have been made in clinical, pathological staging systems, but Dr. Ibrahim says it’s still difficult to determine what to do with borderline cases. He talks about the need to determine frequency and inChoosing the Right Resurfacing Treatment
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/choosing-the-right-resurfacing-treatment/20141/Joel L. Cohen, MD discusses how he assesses the area around the mouth to determine the best resurfacing treatment option. From fine lines and etching around the mouth to issues with pigmentation and redness, he says there are many options from low-downtime treatments to full-field erbium treatments.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveDermWireTV: Arcutis Takes PASI HD; Galderma at Camp Wonder; Amgen Challenge; LaRoche-Posay Pride
https://practicaldermatology.com/topics/psoriasis/dermwiretv-arcutis-takes-pasi-hd-galderma-at-camp-wonder-amgen-challenge-laroche-posay-pride/19996/The PASI high discrimination or PASI-HD tool was developed by Arcutis Biotherapeutics in collaboration with a panel of psoriasis research experts. Led by Amgen, in partnership with the International Federation of Psoriasis Associations, the Understanding Psoriatic Disease Leveraging Insights for TreConnecting and Networking at DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/connecting-and-networking-at-derm2021/19995/Kara S. Gooding, MMS, PA-C says being able to connect with colleagues in sessions and at social events were an invaluable part of the DERM2021 NP/PA CME Conference.Hair Care Trends You Need to Know
https://practicaldermatology.com/conferences/aad-summer-2021/hair-care-trends-you-need-to-know/19976/People are sharing more than their latest dance moves on TikTok. Many—with no background in science—are dispensing hair care advice, some of which could even be dangerous. Learn which trends you should know about in order to educate your patients about what really works versus what could do more harKeloids: To Cut or Not to Cut
https://practicaldermatology.com/topics/skin-cancer-photoprotection/keloids-to-cut-or-not-to-cut/19987/When treating keloids, ask patients what they want to achieve. Are they hoping to decrease itch or pain? Do they want to flatten or soften the appearance of a keloid? Hilary Baldwin, MD reviews her approach to deciding whether to remove a keloid surgically as well as other treatment options. Plus, sEye Opener
https://practicaldermatology.com/programs/practical-dermatology/eye-opener/19918/From each individual's implicit bias to the systemic bias that influences the tools of research and clinical practice, innumerable factors go into every patient encounter. Only individuals who are open to recognizing and confronting bias can overcome it. Panelists share their personal perspectives oDERM2020 Content Recap: Kara Gooding, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-kara-gooding-pa-c/19841/DERM2020 Faculty Kara Gooding, PA-C talks a bit about the case she presented at DERM2020.COVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, a